Amphastar Eyes Sun Pharma Showdown With US Ganirelix Approval
Other ANDA Sponsor Sun Pharma Had Issued Recall Last Year
Executive Summary
Amphastar is celebrating what it says is its fourth injectable peptide product approval from the USFDA with its generic version of Organon’s ganirelix acetate, in the process setting up a rivalry with Sun Pharma and commercial partner Ferring Pharmaceuticals.
You may also be interested in...
Amphastar Receives FDA Approval For Regadenoson Following Solid Q1
Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.
Amphastar Has First US Glucagon Rival
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction
The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.